Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Current therapy of the pemphigus group.

Kasperkiewicz M, Schmidt E, Zillikens D.

Clin Dermatol. 2012 Jan-Feb;30(1):84-94. doi: 10.1016/j.clindermatol.2011.03.014. Review.

PMID:
22137231
2.

Immunoadsorption in the treatment of pemphigus.

Mlynek A, Meurer M.

Atheroscler Suppl. 2009 Dec 29;10(5):107-9. doi: 10.1016/S1567-5688(09)71822-7.

PMID:
20129386
3.

Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.

Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D.

Br J Dermatol. 2008 Feb;158(2):382-8. Epub 2007 Dec 6.

PMID:
18070210
4.

Treatment of severe pemphigus vulgaris of the scalp with adjuvant rituximab and immunoadsorption.

Kamphausen I, Schulze F, Schmidt E, Zillikens D, Kunz M.

Eur J Dermatol. 2012 Nov-Dec;22(6):786-7. doi: 10.1684/ejd.2012.1843. No abstract available.

PMID:
23114083
5.

Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.

Behzad M, Möbs C, Kneisel A, Möller M, Hoyer J, Hertl M, Eming R.

Br J Dermatol. 2012 Apr;166(4):844-52. doi: 10.1111/j.1365-2133.2011.10732.x.

PMID:
22092243
6.

Management of pemphigus in pediatric patients.

Gürcan H, Mabrouk D, Razzaque Ahmed A.

Minerva Pediatr. 2011 Aug;63(4):279-91. Review.

PMID:
21909064
7.

Current treatment of autoimmune blistering diseases.

Kasperkiewicz M, Schmidt E.

Curr Drug Discov Technol. 2009 Dec;6(4):270-80. Review.

PMID:
20025595
8.

Is it time to re-evaluate the treatment of pemphigus?

Leventhal JS, Sanchez MR.

J Drugs Dermatol. 2012 Oct;11(10):1200-6.

PMID:
23134985
9.

Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.

Baum S, Gilboa S, Greenberger S, Pavlotsky F, Trau H, Barzilai A.

J Dermatolog Treat. 2013 Dec;24(6):427-30. doi: 10.3109/09546634.2013.784391. Epub 2013 May 21.

PMID:
23521340
10.

Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption.

Shimanovich I, Herzog S, Schmidt E, Opitz A, Klinker E, Bröcker EB, Goebeler M, Zillikens D.

Clin Exp Dermatol. 2006 Nov;31(6):768-74. Epub 2006 Jul 4.

PMID:
16824051
11.

Treatment strategies for pemphigus vulgaris in Japan.

Hashimoto T.

Expert Opin Pharmacother. 2008 Jun;9(9):1519-30. doi: 10.1517/14656566.9.9.1519 . Review.

PMID:
18518782
12.

Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.

Feldman RJ, Christen WG, Ahmed AR.

Br J Dermatol. 2012 Mar;166(3):511-7. doi: 10.1111/j.1365-2133.2011.10658.x. Epub 2012 Jan 19.

PMID:
21967407
13.

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

Ahmed AR, Spigelman Z, Cavacini LA, Posner MR.

N Engl J Med. 2006 Oct 26;355(17):1772-9.

14.

Treatment of pemphigus vulgaris with protein A immunoadsorption: case report of long-term history showing favorable outcome.

Frost N, Messer G, Fierlbeck G, Risler T, Lytton SD.

Ann N Y Acad Sci. 2005 Jun;1051:591-6.

PMID:
16126999
15.

The actual management of pemphigus.

Daniel BS, Murrell DF.

G Ital Dermatol Venereol. 2010 Oct;145(5):689-702. Review.

PMID:
20930702
16.

Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).

Kong HH, Prose NS, Ware RE, Hall RP 3rd.

Pediatr Dermatol. 2005 Sep-Oct;22(5):461-4.

PMID:
16191003
17.

Recalcitrant pemphigus vulgaris: aseptic meningitis associated with intravenous immunoglobulin therapy and successful treatment with rituximab.

Ventura F, Rocha J, Fernandes JC, Machado A, Brito C.

Int J Dermatol. 2013 Apr;52(4):501-2. doi: 10.1111/j.1365-4632.2010.04870.x. Epub 2013 Mar 3. No abstract available.

PMID:
23451774
18.

Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.

Kim MR, Kim HC, Kim SC.

Dermatology. 2011;223(2):182-8. doi: 10.1159/000332848. Epub 2011 Oct 21.

PMID:
22025028
19.

New and innovative interventions in the management of pemphigus.

Frydman AS, Fairley JA.

G Ital Dermatol Venereol. 2011 Jun;146(3):211-24. Review.

PMID:
21566551
20.

Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients.

Matsukura S, Knowles SR, Walsh S, Shear NH.

Arch Dermatol. 2012 Jun;148(6):734-9. doi: 10.1001/archdermatol.2011.3320. Erratum in: Arch Dermatol. 2012 Sep 1;148(9):1012. Dosage error in article text. Arch Dermatol. 2012 Aug;148(8):970. Dosage error in article text.

PMID:
22351790

Supplemental Content

Support Center